Companies
Sutro Biopharma
XpressCF® platform on E. coli/CHO lysate — antibodies and ADCs, reactors to thousands of litres.
- Country
- United States
FDA GMP
ISO 9001
Coverage
| CN | EU | US | |
|---|---|---|---|
| foundries-design | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2003 | ir.sutrobio.com · sutrobio.com |
| Headcount | 134 (as of March 2026) | sec.gov |
| Headquarters | South San Francisco, California | ir.sutrobio.com · sutrobio.com |
| Production site | San Carlos, California (operations ceased, exit expected in 2026) | pharmamanufacturing.com |
| Capacity | Commercial scale manufacturing performed by external CMOs, such as 4,500L batches at Boehringer Ingelheim's facility | pharmamanufacturing.com · sutrobio.com |
Independent sources: ir.sutrobio.com · pharmamanufacturing.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Cell-free systems & cell-free bioproduction | foundries-design | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.